Piramal Builds GI Play With OTC Acquisitions
This article was originally published in Scrip
Executive Summary
Piramal Enterprises' consumer products unit has acquired five brands from Organon India Pvt Ltd and MSD BV for INR920m ($13.8m), as it expands its offering in the fast growing gastrointestinals segment in India.
You may also be interested in...
Piramal Stays The M&A Course; Snaps Up Niche Mallinckrodt Assets
India’s Piramal group continues its buying spree, snapping up Mallinckrodt’s intrathecal therapy business, as it seeks limited competition niches to plough deeper into the $20bn-plus global generic injectable hospital drugs market.
Dr Reddy’s Gears For Generic Revlimid Run In US, Quarterly ‘Blips’ Aside
Quarterly ups and down notwithstanding, Dr Reddy’s signals continuing US launch momentum, with its generic Revlimid, for which the Indian firm claims exclusivity for two strengths, set to hit the market next month. “Low competition” assets, especially injectables, also continue to be on the deal-making radar in the US.
Dr Reddy’s Gears For Generic Revlimid Run In US, Quarterly ‘Blips’ Aside
Quarterly ups and down notwithstanding, Dr Reddy’s signals continuing US launch momentum, with its generic Revlimid, for which the Indian firm claims exclusivity for two strengths, set to hit the market next month. “Low competition” assets, especially injectables, also continue to be on the deal-making radar in the US.